1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2024

EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2024

Summary

Growth hormone deficiency (GHD) is an endocrine disorder characterized by low or deficient secretion of growth hormone (GH) secondary to malfunction of the pituitary gland, a pea-sized structure located at the base of the brain that is responsible for the production of GH. The International Classification of Diseases (ICD-10) ICD-10-CM code for GHD is E23.0.

GHD in children can be classified as idiopathic or organic, which is further divided into congenital and acquired. GH is necessary for normal growth, as it fuels childhood growth and development. In an adult’s normal lifespan, GH is needed to maintain the amounts of body fat, muscle, and bone necessary for sustaining tissue and organ function. GHD acquired in adulthood is usually acquired through damage to the pituitary-hypothalamic region through trauma or tumors. This report does not cover childhood-onset GHD that progresses into adulthood.

In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes will increase from 97,985 cases in 2014 to 100,494 cases in 2024, at an Annual Growth Rate (AGR) of 0.26%. GlobalData epidemiologists forecast a small increase in the AGR of the diagnosed prevalent cases of GHD from 2014-2024 for all included markets except for Germany and Japan. The majority of diagnosed prevalent cases of GHD in children in the 7MM are in boys. In the 7MM, 68.05% of the GHD cases in children are in boys and the trend is consistent in the individual markets. In adults, the distribution is also skewed towards men in the US and the 5EU.

GlobalData epidemiologists maintained consistent forecast methodology across all the 7MM, thus allowing for a meaningful comparison of the included parameters across the 7MM.

Scope

- The Growth Hormone Deficiency (GHD) EpiCast Report provides an overview of the risk factors and global trends of GHD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the GHD diagnosed in children (=18 years) and in adults (>18 years) segmented by sex from 2014-2024. The forecast also provides GHD diagnosed cases in children segmented by the etiological classifications (idiopathic and organic; organic further segmented into congenital and acquired). The forecast for GHD diagnosed in adults are further segmented by etiological classifications (idiopathic and acquired).
- The GHD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global GHD market.
- Quantify patient populations in the global GHD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GHD therapeutics in each of the markets covered.
- Identify the percentage of GHD diagnosed prevalent cases by etiological classification.

Table Of Contents

EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2024
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 6
2.3 Upcoming Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.1.1 GHD in Children 8
3.1.2 GHD in Adults 9
3.2 Risk Factors and Comorbidities 9
3.3 Global Trends 11
3.3.1 GHD in Children 12
3.3.2 GHD in Adults 14
3.4 Forecast Methodology 15
3.4.1 Sources Used 19
3.4.2 Sources Not Used 23
3.4.3 Forecast Assumptions and Methods 24
3.5 Epidemiological Forecast of GHD (2014-2024) 27
3.5.1 Diagnosed Prevalent Cases of GHD 27
3.5.2 Diagnosed Prevalent Cases of GHD by Sex 29
3.5.3 Diagnosed Prevalent Cases of GHD by Age 30
3.5.4 Age-Adjusted Diagnosed Prevalence of GHD 33
3.5.5 Diagnosed Prevalent Cases of GHD in Children by Etiological Classification 34
3.5.6 Diagnosed Prevalent Cases of GHD in Adults by Etiological Classification 35
3.6 Discussion 36
3.6.1 Epidemiological Forecast Insight 36
3.6.2 Limitations of the Analysis 37
3.6.3 Strengths of the Analysis 38
4 Appendix 39
4.1 Bibliography 39
4.2 About the Authors 43
4.2.1 Epidemiologists 43
4.2.2 Reviewers 43
4.2.3 Global Director of Therapy Analysis and Epidemiology 44
4.2.4 Global Head of Healthcare 45
4.3 About GlobalData 46
4.4 About EpiCast 46
4.5 Disclaimer 47

1.1 List of Tables
Table 1: Risk Factors for GHD 10
Table 2: 7MM, Sources for the Diagnosed Cases of GHD in Children 17
Table 3: 7MM, Sources for the Prevalent Cases of GHD Diagnosed in Adults 17
Table 4: 7MM, Sources for the Etiological Classifications of Diagnosed Prevalent Cases of GHD in Children 18
Table 5: 7MM, Sources for the Etiological Classifications of Diagnosed Prevalent Cases of GHD in Adults 19
Table 6: 7MM, Diagnosed Prevalent Cases of GHD, All Ages, Both Sexes, N, Selected Years 2014-2024 28
Table 7: 7MM, Diagnosed Prevalent Cases of GHD by Sex, Children and Adults, N (Row %), 2014 29
Table 8: 7MM, Diagnosed Prevalent Cases of GHD in Children, Both Sexes, Ages ?18 Years, N, Selected Years 2014-2024 31
Table 9: 7MM, Diagnosed Prevalent Cases of GHD in Adults, Both Sexes, Ages >18 Years, N, Selected Years 2014-2024 32
Table 10: 7MM, Diagnosed Prevalent Cases of GHD by Etiological Classification, N (Col %), Both Sexes, Ages ?18, 2014 35
Table 11: 7MM, Diagnosed Prevalent Cases of GHD in Adults by Etiological Classification, N (Row %), Both Sexes, Ages >18, 2014 36

1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalence of GHD in Children, Both Sexes, Ages ?18 Years 14
Figure 2: 7MM, Diagnosed Prevalence of GHD in Adults, Both Sexes, Ages >18 Years 15
Figure 3: Case-Flow for GHD Epidemiological Forecast 16
Figure 4: 7MM, Diagnosed Prevalent Cases of GHD, Both Sexes, All Ages, N, 2014-2024 28
Figure 5: 7MM, Age-Specific Diagnosed Prevalent Cases of GHD, Both Sexes, Ages ?18 Years, 2014 31
Figure 6: 7MM, Age-Specific Diagnosed Prevalent Cases of GHD, Both Sexes, Ages >18 Years, 2014 33
Figure 7: 7MM, Age-Standardized Diagnosed Prevalence of GHD, All Ages, by Sex, 2014 34

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.